United States: Animal Compounding Guidance (Draft) For Use Of Bulk Drug Substances Released By FDA Today

Last Updated: May 19 2015
Article by Brian J. Malkin

On May 18, 2015, FDA released new draft guidance on animal drug compounding from bulk drug substances. While FDA's current statutory framework and regulations do not permit compounding of animal drugs from bulk drug substances, FDA now recognizes that there are limited circumstances when an animal drug may be compounded from bulk substance. In particular, there are certain circumstances where there is no approved drug that can be used or modified through compounding to treat a particular animal with a particular condition. FDA's new guidance #230: Compounding Animal Drugs from Bulk Drug Substances further describes the circumstances where the Agency does not intend to take action against state-licensed pharmacies, veterinarians, and facilities registered as outsourcing facilities, when drugs are compounded for animals from bulk drug substances. The Guidance does not apply to compounding animal drugs from approved new animal or human drugs, which may be conducted according to Section 512(a)(4) and (5) of the Federal Food, Drug and Cosmetic Act ("FD&C Act") (21 C.F.R. Part 530). These uses are considered "extralabel use", which has an exemption for such use under Section 502(f) of the FD&C Act e.g., use of a human chemotherapy drug to treat cancer compounded for use in dogs or cats, when the chemotherapy drug is approved for those specific animal species.

FDA's Director of the Center for Veterinary Medicine, Bernadette, Dunham, D.V.M., Ph.D., stated: "This draft guidance, once finalized, will help to ensure that animal drugs compounded from bulk drug substances are available for patient care without compromising the animal drug approval process or jeopardizing the safety of the food supply."

The Guidance proposes that such animal drug compounding may occur from bulk drug by or under the direct supervision of a licensed pharmacist in a state-licensed pharmacy when, among other things:

  • The drug is dispensed after receipt of valid prescription from a veterinarian for an individually-identified animal patient that comes directly from the prescribing veterinarian or the patients owner or caretaker to the compounding facility. Advance quantities may be compounded for an amount that does not exceed the amount that the state-licensed pharmacy compounded pursuant to patient-specific prescriptions based on such history for that drug product over any consecutive 14-day periods within the last 6 months.
  • The drug is not intended for food-producing animals with a prescription with the statement: "This patient is not a food-producing animal." Whether or not the food-producing animal, e.g., cattle, swine, chicken, turkey, sheep, goats, or non-ornamental fish, is actually intended to be introduced into food chain is not relevant for this consideration.
  • If the drug contains a bulk drug substance from a human or animal drug approved for marketing by FDA, then any change in the drug must be identified by the veterinarian prescribing the compounded drug along with the documented reason why the change would produce a clinical difference for that individually-identified animal patient and cannot be compounded from the human or animal drug, e.g., the approved animal or human drug contains a dose so large that it cannot be divided or diluted to the dose required by the specific animal, i.e., extralabel use is not possible.
  • The pharmacy must receive along with the prescription documentation and a statement: "There are no FDA-approved animal or human drugs that can be used as labeled or in an extralabel manner under section 512(a)(4) or (5) and 21 CFR part 530 to appropriately treat the disease, symptom, or condition for which this drug is being prescribed."
  • The bulk drug substances used must be manufactured by an establishment registered under Section 510 of the FD&C Act along with a valid certificate of analysis.
  • The drug is compounded according to Chapters <795> and <797> of the United States Pharmacopeia and National Formulary ("USP-NF"), including sterile drug compounding.
  • The drug is not sold or transferred by an entity other than the entity that compounded the drug.
  • Within 15 days of becoming aware of any product defect or serious adverse event associated with the drug compounded from bulk drug substances, the pharmacy reports it to FDA on Form FDA 1932a.
  • The label of the compounded drug indicates the species of the intended animal patient, the name of the animal patient, and the name of the owner or caretaker of the animal patient.

For animal drugs compounded by a licensed veterinarian, the conditions for compounding using bulk drug substances are similar with the following modifications:

  •  The drug is compounded and dispensed by a veterinarian to treat an individually-identified animal patient under his care.
  • There are no FDA-approved animal or human drugs that can be used as labeled or in an extralabel manner under section 512(a)(4) or (5) and 21 CFR Part 530 to appropriately treat the disease, symptom, or condition for which this drug is being prescribed.
  • These provisions do not appear to include similar provisions for advance compounding as with the pharmacy.

For animal drugs compounded by an outsourcing facility, the provisions are similar with the following modifications:

The drugs are compounded only from bulk substances appearing in the appendix list to be developed in conjunction with this Guidance.

  • The drug is compounded by or under the supervision of a licensed pharmacist.
  • The drug is compounded in accordance with cGMP requirements.
  • These provisions also do not appear to include similar provisions for advance compounding as with the pharmacy.
  • All drugs compounded by animals by an outsourcing facility are included in the report required by 503B of the FD&C Act to be submitted to FDA each June and December identifying the drugs made by the outsourcing facility during the previous 6-month period, along with the active ingredients and their source(s), NDC number of the source ingredient(s), strength of the active ingredient(s) per unit, the dosage form and route of administration, package description, number of individual units produced, and the NDC number of the final product, if assigned, along with which reported drugs were intended for animal use.
  • The veterinarian's prescription or order states that the drug is intended to treat the species and condition(s) for which the substance is listed in the appendix developed in conjunction with the Guidance.
  • Certain product labeling, including language such as "Not for resale.", "Compounded by [name of outsourcing facility]" and "Adverse events associated with this compounded drug should be reported to FDA on Form FDA 1932a."

Along with the Guidance, FDA is developing a list of bulk drug substances that facilities registered as outsourcing facilities under section 503B of the FD&C Act can use to compound for an individual animal patient or veterinarian office use under specified conditions. FDA is soliciting in a Federal Register notice to publish tomorrow public input on which bulk drug substances should be placed on the list. The draft Guidance and nominations for the list of bulk drug substances will have 90 days for comment. Following the initial list, FDA intends to review the nominated bulk drug substances on a rolling basis to periodically update the list. Finally, FDA also withdrew Compliance Policy Guide Section 608.400 Compounding of Drugs for Use in Animals, because the Agency said it was no longer consistent with its current thinking on these issues.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.